Surmodics INC: insider trades · United States · SEC (Form 4)

About Surmodics INC

Surmodics Inc. is a U.S.-based medical technology company listed on the NASDAQ market in the United States, focused on advanced surface technologies, interventional medical devices, and in vitro diagnostics components. Founded in 1979 and headquartered in Eden Prairie, Minnesota, the company built its franchise on deep expertise in surface science, with a recognized position in hydrophilic, hemocompatible, and drug-delivery coatings for intravascular medical devices. Over time, Surmodics has evolved from a specialized coatings business into a broader development and manufacturing partner, combining design, formulation, testing, scale-up, and production capabilities for complex medical products. The company is organized around several complementary business lines. Performance Coatings remains the historical core: these technologies are designed to improve lubricity, trackability, and overall procedural performance of devices used in coronary, peripheral, neurovascular, and structural heart applications. Its In Vitro Diagnostics business supplies chemical components, surfaces, and related materials used in immunoassays and microarrays, providing diversification beyond interventional medtech. Surmodics also offers Contract Development & Manufacturing services, including catheter and complex-device manufacturing capabilities, with operations in the U.S. and Ireland. In addition, its Interventional Products portfolio includes therapies for peripheral arterial and venous disease, such as the Pounce and Sublime platforms, alongside drug-coated balloon technology under the SurVeil brand. From a competitive standpoint, Surmodics is a focused niche player rather than a large diversified medtech conglomerate. Its edge comes from technical depth, intellectual property, coating performance, and its ability to support customers from concept through commercialization. In a highly regulated industry, the company benefits from long-standing relationships with major medical device manufacturers, innovative startups, and strategic global partners. Geographically, the business remains centered in the United States, with Eden Prairie as the main hub and a meaningful industrial footprint in Ireland. Recent company highlights have centered on product pipeline expansion and commercialization milestones. Surmodics has highlighted broader clinical use of its Preside coating platform, new releases within the Pounce thrombectomy family, and continued progress in its drug-coated balloon franchise. For investors, the core question is whether Surmodics can convert its technology platform into sustained commercial growth while managing the regulatory, reimbursement, and competitive pressures inherent to medtech innovation.